MiniMed Group, Inc. Common Stock (MMED)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MiniMed Group, Inc. Common Stock (MMED) trades at $15.39. MiniMed Group, Inc. specializes in developing, manufacturing, and marketing medical devices and solutions for diabetes management. Market cap: $4.32B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for MMED: MMED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MMED against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MMED: 1/1 perspectives are bearish.
MiniMed Group, Inc. Common Stock (MMED) Healthcare & Pipeline Overview
MiniMed Group, Inc. is a key player in the diabetes management solutions market, offering insulin pumps, continuous glucose monitoring systems, and related accessories. Founded in 1983, the company focuses on improving blood glucose control for patients and healthcare providers, holding a significant position in the medical care facilities sector.
What Is the Investment Thesis for MMED?
MiniMed Group, Inc. presents a mixed investment thesis. The company's established presence in the diabetes management market, coupled with its comprehensive product portfolio, offers a stable revenue base. The aging population and increasing prevalence of diabetes globally are expected to drive demand for MiniMed's products. However, the company's negative P/E ratio of -17.70 and a negative profit margin of -9.2% raise concerns about its profitability. Future growth hinges on MiniMed's ability to innovate and introduce next-generation diabetes management solutions. Investors should monitor the company's progress in improving its financial performance and capitalizing on growth opportunities in the expanding diabetes care market. The company's gross margin of 56.2% indicates potential for profitability if operational efficiencies are improved.
Based on FMP financials and quantitative analysis
MMED Key Highlights
- Market capitalization of $4.43 billion reflects MiniMed's significant presence in the diabetes management market.
- Gross margin of 56.2% indicates the company's ability to maintain a healthy profit on its sales after accounting for the cost of goods sold.
- Negative P/E ratio of -17.70 suggests that the company is currently not profitable, requiring further investigation into its earnings potential.
- The company's focus on insulin pumps and continuous glucose monitoring systems positions it to benefit from the growing demand for advanced diabetes management solutions.
- MiniMed's established presence and reputation in the healthcare sector provide a competitive advantage in attracting and retaining customers.
Who Are MMED's Competitors?
Who Are MMED's Competitors?
MMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DXCM DexCom, Inc. | $72.77 | +1.94% | $28.08B | 52 |
| TNDM Tandem Diabetes Care, Inc. | $17.52 | -5.14% | $1.20B | 52 |
| ABT Abbott Laboratories | $91.36 | +0.95% | $159.13B | 48 |
| HSMD Healthcare Solutions Management Group, Inc. | $0.00 | +0.00% | 18K | 66 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| GNOW American Caresource Holdings, Inc. | $0.00 | +0.00% | 860K | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| LWSCF Sienna Senior Living Inc. | $15.35 | +0.85% | $1.53B | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MMED's Key Strengths?
- Established presence in the diabetes management market.
- Comprehensive product portfolio of insulin pumps and CGM systems.
- Strong brand reputation and customer loyalty.
- Focus on innovation and technological advancements.
What Are MMED's Weaknesses?
- Negative P/E ratio and profit margin.
- Dependence on insulin pump and CGM sales.
- Exposure to competition from other medical device manufacturers.
- Potential for product recalls or safety concerns.
What Could Drive MMED Stock Higher?
- Launch of next-generation continuous glucose monitoring (CGM) system with improved accuracy and user experience.
- Expansion into emerging markets with high diabetes prevalence, such as India and China.
- Strategic partnerships with healthcare providers to promote product adoption and patient education.
- Integration of diabetes management solutions with digital health platforms for personalized insights and remote monitoring.
What Are the Key Risks for MMED?
- Intense competition from established and emerging players in the diabetes management market.
- Regulatory changes and reimbursement pressures impacting pricing and market access.
- Technological disruptions and obsolescence of existing product lines.
- Negative P/E ratio and profit margin indicating financial challenges.
- Product recalls or safety concerns affecting brand reputation and customer trust.
What Are the Growth Opportunities for MMED?
- Expansion into Emerging Markets: MiniMed can capitalize on the increasing prevalence of diabetes in emerging markets such as India and China. These regions have a large and growing population of individuals with diabetes, creating a significant demand for diabetes management solutions. By establishing a presence in these markets and tailoring its products to meet local needs, MiniMed can drive revenue growth. The diabetes care market in Asia-Pacific is expected to witness substantial growth, offering a lucrative opportunity for MiniMed to expand its global footprint. Timeline: Ongoing.
- Development of Next-Generation CGM Systems: MiniMed can invest in the development of next-generation continuous glucose monitoring (CGM) systems that offer improved accuracy, convenience, and integration with insulin delivery devices. These advanced CGM systems can provide real-time glucose data and predictive alerts, enabling individuals with diabetes to make more informed treatment decisions. By launching innovative CGM systems, MiniMed can attract new customers and strengthen its market position. The market for advanced CGM systems is projected to grow significantly, driven by the demand for more effective diabetes management solutions. Timeline: Ongoing.
- Integration with Digital Health Platforms: MiniMed can integrate its diabetes management solutions with digital health platforms and mobile apps to provide users with a comprehensive and connected experience. By partnering with digital health companies, MiniMed can offer personalized insights, remote monitoring, and virtual coaching to individuals with diabetes. This integration can enhance patient engagement and improve treatment outcomes. The digital health market is rapidly expanding, offering a significant opportunity for MiniMed to leverage technology to enhance its diabetes care offerings. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: MiniMed can forge strategic partnerships with healthcare providers, including hospitals, clinics, and diabetes centers, to promote the adoption of its diabetes management solutions. By collaborating with healthcare professionals, MiniMed can educate patients about the benefits of its products and ensure that they receive proper training and support. These partnerships can drive sales and strengthen MiniMed's reputation as a trusted provider of diabetes care solutions. Timeline: Ongoing.
- Expansion of Product Portfolio: MiniMed can expand its product portfolio to include a wider range of diabetes management solutions, such as smart insulin pens, closed-loop systems, and artificial pancreas devices. By offering a comprehensive suite of products, MiniMed can cater to the diverse needs of individuals with diabetes and capture a larger share of the market. The market for advanced diabetes management technologies is expected to grow significantly, driven by the demand for more effective and convenient treatment options. Timeline: Ongoing.
What Opportunities Does MMED Have?
- Expansion into emerging markets with growing diabetes prevalence.
- Development of next-generation CGM systems with improved accuracy.
- Integration with digital health platforms for personalized insights.
- Strategic partnerships with healthcare providers to promote product adoption.
What Threats Does MMED Face?
- Intense competition from established and emerging players.
- Regulatory changes and reimbursement pressures.
- Technological disruptions and obsolescence.
- Economic downturns and healthcare spending cuts.
What Are MMED's Competitive Advantages?
- Established brand reputation in the diabetes management market.
- Proprietary technology in insulin pump and CGM systems.
- Extensive distribution network reaching patients and healthcare providers.
- Strong relationships with healthcare professionals and key opinion leaders.
What Does MMED Do?
Founded in 1983 by Alfred E. Mann, MiniMed Group, Inc. has evolved into a prominent player in the diabetes management industry. The company is headquartered in Northridge, CA, and is dedicated to the development, manufacturing, and marketing of medical devices and solutions aimed at improving the lives of individuals with diabetes. MiniMed's core offerings include a range of insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, and software platforms designed to help patients and healthcare providers effectively monitor and control blood glucose levels. These products are integral in delivering precise insulin dosages and providing real-time glucose data, enabling more informed treatment decisions. Over the years, MiniMed has focused on innovation and technological advancements to enhance the accuracy, reliability, and user-friendliness of its devices. The company's commitment to research and development has led to the introduction of advanced CGM systems that offer predictive alerts and integrated insulin delivery systems that automate the process of glucose management. MiniMed's products are distributed globally, reaching patients and healthcare providers across various regions. The company's focus on patient education and support further strengthens its market position, ensuring that users can effectively utilize its products to manage their diabetes. MiniMed faces competition from other medical device manufacturers in the diabetes care space, but its long-standing reputation and comprehensive product portfolio provide a strong competitive edge.
What Products and Services Does MMED Offer?
- Develops and manufactures insulin pumps for precise insulin delivery.
- Offers continuous glucose monitoring (CGM) systems for real-time glucose data.
- Provides infusion sets for insulin pump users.
- Creates software platforms for diabetes data management.
- Markets related accessories for diabetes management devices.
- Offers solutions for effective blood glucose level monitoring and control.
How Does MMED Make Money?
- Generates revenue through the sale of insulin pumps and CGM systems.
- Derives income from the sale of disposable infusion sets and accessories.
- Offers software platforms and data management services for recurring revenue.
- Partners with healthcare providers to promote product adoption.
What Industry Does MMED Operate In?
MiniMed Group, Inc. operates within the medical care facilities sector, which is experiencing growth due to the increasing prevalence of chronic diseases like diabetes. The diabetes care market is driven by technological advancements in glucose monitoring and insulin delivery systems. Competition is intense, with companies vying to offer more accurate, convenient, and integrated solutions. MiniMed's focus on insulin pumps and CGM systems aligns with the industry's trend toward personalized and automated diabetes management. The global diabetes care devices market is projected to reach significant growth in the coming years, driven by the rising incidence of diabetes and the demand for advanced monitoring and treatment options.
Who Are MMED's Key Customers?
- Individuals with type 1 diabetes requiring insulin therapy.
- Individuals with type 2 diabetes needing advanced glucose management.
- Healthcare providers, including endocrinologists and diabetes educators.
- Hospitals and clinics specializing in diabetes care.
MMED Financials
MMED Latest News
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jun 3, 2026
-
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
benzinga · Jun 3, 2026
-
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
MT Newswires · Jun 3, 2026
-
Earnings Scheduled For June 3, 2026
benzinga · Jun 3, 2026
MMED Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MMED.
Price Targets
Wall Street price target analysis for MMED.
MMED MoonshotScore
What does this score mean?
The MoonshotScore rates MMED's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are MMED's Competitors?
Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
Earnings Scheduled For June 3, 2026
Leadership: Que Thanh Dallara
CEO
Que Thanh Dallara is the Chief Executive Officer of MiniMed Group, Inc. She has extensive experience in the medical device industry, with a proven track record of driving growth and innovation. Prior to joining MiniMed, Dallara held leadership positions at various healthcare companies, where she oversaw product development, marketing, and sales initiatives. Her expertise lies in developing and commercializing innovative medical technologies that improve patient outcomes. Dallara holds a degree in Biomedical Engineering and an MBA from a leading business school.
Track Record: Since assuming the role of CEO, Que Thanh Dallara has focused on strengthening MiniMed's market position and driving innovation in diabetes management. She has overseen the launch of new CGM systems and expanded the company's partnerships with healthcare providers. Dallara's strategic decisions have contributed to revenue growth and improved operational efficiency. She is committed to delivering value to shareholders and improving the lives of individuals with diabetes.
What Investors Ask About MiniMed Group, Inc. Common Stock (MMED) — Healthcare
What does MiniMed Group, Inc. Common Stock do?
MiniMed Group, Inc. specializes in the development, manufacturing, and marketing of medical devices and solutions for diabetes management. Its primary offerings include insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, and software platforms. These products are designed to help individuals with diabetes and their healthcare providers effectively monitor and control blood glucose levels, improving overall health outcomes. The company's focus is on providing innovative and user-friendly solutions for diabetes care.
What do analysts say about MMED stock?
Analyst coverage of MiniMed Group, Inc. is currently limited. Key valuation metrics, such as the negative P/E ratio, suggest caution. Growth considerations center on the company's ability to innovate and expand its market share in the competitive diabetes management industry. Investors should monitor the company's financial performance and product pipeline to assess its long-term potential. Analyst sentiment is pending further data and developments.
What are the main risks for MMED?
MiniMed Group, Inc. faces several risks, including intense competition from other medical device manufacturers in the diabetes care space. Regulatory changes and reimbursement pressures could impact pricing and market access. Technological disruptions and the potential for product recalls or safety concerns also pose significant risks. The company's current negative P/E ratio and profit margin highlight financial challenges that need to be addressed to ensure long-term sustainability.
What are the key factors to evaluate for MMED?
Evaluating MMED involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Established presence in the diabetes management market. Primary risk to monitor: Intense competition from established and emerging players in the diabetes management market. This is not financial advice.
How frequently does MMED data refresh on this page?
MMED prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MMED's recent stock price performance?
Recent price movement in MiniMed Group, Inc. Common Stock (MMED) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the diabetes management market. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MMED overvalued or undervalued right now?
Determining whether MiniMed Group, Inc. Common Stock (MMED) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MMED?
Before investing in MiniMed Group, Inc. Common Stock (MMED), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending and may provide further insights.
- Financial data is based on the most recent available information.
- Market conditions and competitive landscape are subject to change.